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Abstract
Background: Collecting adequate information on key epidemiological indicators is a prerequisite to informing a
public health response to reduce the impact of hepatitis C virus (HCV) infection in Malaysia. Our goal was to
overcome the acute data shortage typical of low/middle income countries using statistical modelling to estimate
the national HCV prevalence and the distribution over transmission pathways as of the end of 2009.
Methods: Multi-parameter evidence synthesis methods were applied to combine all available relevant data
sources - both direct and indirect - that inform the epidemiological parameters of interest.
Results: An estimated 454,000 (95% credible interval [CrI]: 392,000 to 535,000) HCV antibody-positive individuals
were living in Malaysia in 2009; this represents 2.5% (95% CrI: 2.2–3.0%) of the population aged 15–64 years. Among
males of Malay ethnicity, for 77% (95% CrI: 69–85%) the route of probable transmission was active or a previous history
of injecting drugs. The corresponding proportions were smaller for male Chinese and Indian/other ethnic groups
(40% and 71%, respectively). The estimated prevalence in females of all ethnicities was 1% (95% CrI: 0.6 to 1.4%);
92% (95% CrI: 88 to 95%) of infections were attributable to non-drug injecting routes of transmission.
Conclusions: The prevalent number of persons living with HCV infection in Malaysia is estimated to be very high.
Low/middle income countries often lack a comprehensive evidence base; however, evidence synthesis methods
can assist in filling the data gaps required for the development of effective policy to address the future public health
and economic burden due to HCV.
Keywords: Hepatitis C virus, Prevalence, Bayesian evidence synthesis, People who inject drugs, Malaysia
Background
The burden of hepatitis C virus (HCV) infection and its
epidemiology in Malaysia are still to be documented. Al-
though several studies of drug-using populations and
clinical series of HCV patients in Malaysia have been con-
ducted [1-5], very little is known regarding the population-
level prevalence and the distribution over transmission
pathways [6].
The HIV/AIDS epidemic in Malaysia has drawn con-
siderable governmental and public support, with com-
prehensive screening, harm reduction services for people
who inject drugs (PWID, who represent 67% of reported
cases as of 2012 [7]), and antiretroviral therapy (ART)
treatment now widely available. HIV is now recognised as
being under control [7]. Harm reduction initiatives aimed
at reducing HIV transmission were rolled out in 2005 and
have been rapidly expanded since. Although these initia-
tives have had added benefit for HCV by virtue of address-
ing shared routes of transmission, resources for HCV
testing and treatment are lacking in comparison with those
for HIV.
HCV antibody testing is currently carried out in blood
donor sites, opiate substitution treatment (OST) and drug
rehabilitation centres, prison, antenatal clinics, hospital
and general practice settings; however, screening can only
be considered comprehensive for prospective blood do-
nors. A system for notification of HCV-infected individuals
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to the Ministry of Health has been in place since 2003, but
notifications are mostly from opportunistic screening as
described above, and thus cannot serve as an indicator
of incidence. As of the end of 2013, a cumulative total
of 12,380 HCV cases have been notified (Disease Control
Division, Ministry of Health, pers. comm.).
Malaysia has a recognised illicit drug use problem, with
injecting drug use alarmingly prevalent historically. The
National Anti-Drugs Agency (NADA) reported approxi-
mately 328,500 drug users registered (i.e., tested positive
and arrested) in the period 1988–2009. Drug preferences
and practices fluctuate over time, but 32–42% of all
registrations in the period 2005–2009 were associated
with heroin [8]. Although injecting drug use is consid-
ered by infectious disease experts to be the dominant
mode of HCV transmission in Malaysia, consistent with
data on risk distributions in a number of developed coun-
tries [9], no evidence exists to support this presumption.
Available data on the distribution over transmission routes
is primarily from clinical series and other selected pop-
ulations [3,5,6]; the selection bias inherent in this type
of study is well known [9].
Although the eventual aim of eradicating HCV globally
may be possible, there are many public health challenges
that first have to be met at the national level [10]. An
integral strategy of the WHO’s Framework for Global
Action on Viral Hepatitis [11] is the development of
evidence-based policy, and the WHO has recently pub-
lished guidelines for screening and treatment of HCV, [12]
with special attention on prioritising the resources avail-
able to low- and middle-income countries. Given the
lack of a comprehensive HCV evidence base in Malaysia,
methods for overcoming the existing data gaps would be
of unquestionable value for planning the public health re-
sponse to the HCV epidemic.
The goal of this paper is to estimate the HCV antibody-
positive (Ab+) prevalence, and the distribution over trans-
mission routes, of the infected population in Malaysia using
statistical modelling to combine of all of the relevant
evidence. A better understanding of the epidemiology
of HCV is crucial to the development and deployment
of effective prevention and screening programmes, and
for forecasting trends in HCV-related disease.
Methods
Estimation of key epidemiological indicators (i.e., HCV
Ab+ prevalence, number of HCV Ab+ infected persons,
proportions with PWID and non-PWID risk among HCV
Ab+ persons) was conducted within the multi-parameter
evidence-synthesis (MPES) framework, a recently de-
veloped modelling approach useful for combining mul-
tiple data sources to derive estimates for indicators that
cannot easily be measured directly [13-15]. In this ap-
proach, a model is specified for the relationships between
the various data sources and the parameters of interest,
and estimation is typically carried out using Markov-Chain
Monte-Carlo (MCMC) sampling methods. Prior distri-
butions for parameters can be specified as informative or
vague, and the task of the model is to compute the poster-
ior distributions for all parameters. Importantly, uncertainty
is correctly propagated through the model, and can be
expressed as 95% credible intervals (CrIs).
We related the main parameters of interest using Bayes’
Theorem (Eq. 1 below). In this equation, the sole parameter
for which no direct data were available – the probability of
PWID risk given HCV Ab+ status, or P(PWID|HCV+) –
can be expressed if the other probabilities in the equation




P HCVþð Þ ð1Þ
Figure 1 shows the MPES model structure, and lists the
data sources informing each of the three probabilities re-
quired – P(HCV+ |PWID), P(HCV+), and P(PWID) – to
estimate P(PWID|HCV+) and the relevant stratified sub-
population sizes. See Additional file 1: Appendix B for
MPES model equations and prior distributions. All inputs
and estimated values are with respect to the adult popula-
tion aged 15–64 years only.
Data sources and model parameters
As a preliminary step, we conducted a thorough review
of both the published and grey literature on HCV in
Malaysia, and compiled a list of data availability and data
gaps regarding the prevalence and incidence of HCV,
HCV-HIV co-infection, and the demographic character-
istics of the subpopulations at risk of acquiring infec-
tion. See Table 1 for more detailed information on the
data sources contributing to the evidence synthesis, in-
cluding the actual counts or proportions used as inputs
to the MPES model. The contributing data sources rep-
resent a wide range of years (1991–2011); however, as most
sources collected data within the period 2006–2011, the
evidence synthesis is assumed to apply to the year 2009.
We specified a model in which most parameters were
stratified by sex as well as ethnicity (i.e., Malay, Chinese,
Indian/other), as the baseline risks of being an [injecting]
drug user, and of being HCV Ab+ given PWID status
appear to vary according to ethnicity [2,8]. Variation in
HCV prevalence may be due to ethnic differences in
drug-taking and injecting equipment sharing behaviours
[1]; for instance, ethnic Chinese in Singapore were re-
ported to share drugs much less often than other eth-
nicities [18].
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P(HCV+): probability of HCV
The overall probability of HCV Ab+ in the population is
defined as the weighted sum of two probabilities: the
probability of being HCV Ab+ given PWID risk weighted
by the probability of having PWID risk, and the probabil-
ity among individuals with non-PWID risk. The popula-
tion probability of non-PWID risk is defined as (1 – P
(PWID)):
P HCVþð Þ ¼ PðHCVþjPWIDÞP PWIDð Þ
þ P HCVþ nonPWIDÞP nonPWIDð Þjð
P(HCV+ |nonPWID): probability of HCV in persons with
non-PWID risk
To estimate the probability of HCV infection in individ-
uals with non-PWID risk, two blood donor studies were
available [19,20]. The first is a large study of donor blood
specimens collected in 1991–1992 in Kuala Lumpur, which
found an overall HCV seroprevalence of 1.49% [19]; these
data were considered relevant evidence for the synthesis. A
more recent study (2008–2009) conducted in north-eastern
Malaysia reported a HCV seroprevalence of 0.45% [20].
These data were not used, as donor pre-screening at
this time was much more stringent compared with the
early 1990s, and thus there is a risk of greatly under-
estimating the prevalence in non-PWID.
The selected study reported seroprevalence separately
by ethnic group. We adjusted the reported seroprevalence
for the specificity (Spec =99.7%) of the second-generation
assay employed [21] according to the functional relation-
ship between observed prevalence and true prevalence
(see Additional file 1: Appendix B).
In this study, the vast majority of the tested population
was male – only 29 females among 3,540 persons tested –
and there were no positive specimens among the females.
Therefore, it may be incorrect to generalise male preva-
lence to females. As a solution, the female:male positivity
ratios from studies of blood donors in neighbouring coun-
tries (Singapore [22] and Thailand [23]) were included to
inform a model parameter that defines the female preva-
lence as a proportion of the prevalence among males. The
Thai study population consisted of 2,167 blood donors
(July 1999 to June 2000), with observed sex-specific HCV
Figure 1 The multi-parameter evidence synthesis model (depicted as a directed acyclic graph [DAG]) used to estimate the prevalence
of HCV infection and the proportion of HCV Ab+ individuals with PWID and non-PWID modes of transmission. Stratification is by ethnicity
and sex, but for clarity the DAG for males only is shown. Ovals indicate model parameters; rectangles indicate data sources. Distributional and
functional relationships between parameters/data sources are indicated by solid and dashed arrows, respectively.
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Ab prevalences of 3.21 and 1.77% for males and females,
respectively [23]; the female:male positivity ratio was there-
fore 0.551. The Singapore study population consisted of
65,208 blood donors (December 1992 to August 1994),
with observed sex-specific HCV Ab prevalences of 0.389
and 0.298% for males and females, respectively [22]; the
female:male positivity ratio was therefore 0.766. These two
ratios are effectively weighted by study size in the evidence
synthesis model.
P(HCV+ |PWID): probability of HCV in PWID
Two studies were identified that reported the prevalence
of HCV infection among PWID in Malaysia; one con-
sisted of 159 participants enrolled on an agonist clinical
trial [1] and the other was a large study (n = 526) of PWID
in five urban areas who were not in treatment [2,24]. The
overall HCV prevalence in the two studies was 89.9% and
67.1%, respectively. Because the prevalence of HCV in-
fection may be higher among participants recruited in a
clinical or drug treatment setting, compared with the com-
munity setting, only the data from the latter study were in-
corporated in the evidence synthesis, as this study should
be more representative of HCV prevalence among PWID
in general. Prevalence could be determined according to
ethnic group (Table 1). Because 95% of the study partic-
ipants were male, there were insufficient data to infer the
presence of sex differences, and so HCV prevalence in fe-
male PWID was assumed to be identical to prevalence in
male PWID.
P(PWID): probability of PWID in the general population
P(PWID) was estimated using a separate model to simu-
late the population prevalence of PWID as the sum of the
sizes of the cumulative total living active PWID and ex-
PWID subpopulations in 2009. An estimate of the active
PWID population size – 170,000 in 2009 – had been de-
rived using expert consensus [25], but the size of the ex-
PWID population is also required, as ex-PWID may also
be HCV-infected. We developed a simple individual-based
multi-state Markov model of the total PWID population,
under some basic assumptions. Because the consensus es-
timate refers to the prevalence of living active (or current)
PWID, the value of 170,000 was used for model fitting only.
A detailed description of this model, the fitting proced-
ure, and the results are provided in the Additional file 1:
Appendix A. The probability of being PWID was estimated
stratified by ethnicity and sex. The probability of being
PWID according to ethnicity was informed by the dis-
tribution over ethnic groups among the PWID in a
community-based study of PWID [2], and the probability
among females was set to 2.4% of the total P(PWID), which
is based on NADA figures [26].
P(PWID|HCV+): probability of PWID risk among HCV
Ab+ persons
No data were available regarding the distribution over
probable routes of transmission among HCV Ab+ indi-
viduals in the general population. However, the unknown
probability of PWID risk given HCV Ab+ status, or P
Table 1 Data sources and values for informing the MPES model parameters
Model parameter Data Source
P(HCV|PWID, Malay) 293/427 (68.6%) PWID not in treatment; calculated from Reference [2]
P(HCV|PWID, Chinese) 27/45 (60.6%)
P(HCV|PWID, Other) 33/54 (60.6%)
P(PWID) 2.22% Multi-state Markov model (Additional file 1: Appendix A)
Males 97.6% of P(PWID) Criminal justice data [26]
P(PWID, Malay) 427/526 (81.2%) Ethnicity distribution of PWID from Reference [2]
P(PWID, Chinese) 45/526 (8.6%)
P(PWID, Other) 54/526 (10.3%)
Females 2.4% of P(PWID) Criminal justice data [26]
Males
P(HCV|nonPWID, Malay) 28/1713 (1.63%) Blood donors [19]
P(HCV|nonPWID, Chinese) 22/1373 (1.60%)
P(HCV|nonPWID, Other) 3/454 (0.66%)
Females
Ratio (φ) of: P(HCV|nonPWID, female) to P(HCV|nonPWID, male) 55/1716 [males] Blood donors in Thailand [23]
8/451 [females]
200/51414 [males] Blood donors in Singapore [22]
41/13758 [females]
P(HIV|HCV) 40/113 (35%) PWID in the Malaysian fisherman community [28]
McDonald et al. BMC Infectious Diseases 2014, 14:564 Page 4 of 8
http://www.biomedcentral.com/1471-2334/14/564
(PWID|HCV+), stratified by sex and ethnicity, can be
inferred using Bayes’ Theorem (Eq. 1, above). Equivalently,
it was computed as a proportion: the estimated number of
HCV+ persons with PWID risk divided by the estimated
total HCV+ persons. Similarly, the probability of non-
PWID risk given HCV Ab+ status was calculated as the
estimated number of HCV+ persons with non-PWID risk
divided by the estimated total HCV+ persons.
P(HIV+ |HCV+): prevalence of HIV co-infection in HCV Ab+
persons
HIV and HCV share transmission routes, and HIV co-
infection is common in Malaysian PWID and other drug
users; one study reports a HIV co-infection rate of 43%
among HCV-infected drug users not in treatment [2].
HIV co-infection can lead to a lower rate of spontaneous
viral clearance, accelerated disease progression, and worse
outcomes following antiviral therapy [27]. The prevalence
of HIV co-infection among HCV Ab+ individuals does not
influence the other parameters in the MPES model and
can easily be estimated. A recent study in the Malaysian
fishermen community found that 35% of HCV Ab+were
HIV co-infected [28]; the data underlying this prevalence
value were incorporated in the MPES model.
Prevalence of chronic HCV infection
We estimated the size of the living chronically infected
population by incorporating an estimate from a recent
systematic review [29] indicating that 26% of acute infec-
tions spontaneously resolve into the MPES model. As with
the computation of P(HIV+ |HCV+), including this par-
ameter had no influence on the other model parameters,
but allowed uncertainty in the chronically infected popula-
tion size to be correctly estimated.
Posterior distribution sampling
Sampling from the posterior distributions for all parameters
was carried out via MCMC simulation using OpenBUGS
version 3.2 [30] and the BRugs package for R [31], within
the R statistical computing environment (version 3.0.3)
[32]. Two independent chains were run for 10,000 iter-
ations, with the first 5,000 samples discarded as burn-in.
Graphical methods were used to establish convergence of
the chains.
Sensitivity analyses
Additional simulations were conduct to investigate the sen-
sitivity of P(HCV+) and P(PWID|HCV+) to assumptions
regarding parameter values used in the multi-state Markov
model of PWID population size. Two plausible alternative
values for the average duration of injection career, and two
alternatives for excess mortality were tested (see Additional
file 1: Appendix C).
Results
An estimated 453,700 people (95% credible interval [CrI]:
391,700–535,100) were living with HCV infection in
Malaysia in 2009 (2.5% of the population aged 15–64
years), of whom 59% (95% CrI: 50–68%) acquired their
infection through injecting. The total population size with
chronic HCV infection is estimated at 335,200 (95% CrI:
287,500–396,800), which is more than three times the
number of people reported to be living with HIV in 2009
(Figure 2). These aggregate figures conceal variation ac-
cording to sex and ethnicity; the estimated prevalence in
females (1.0%, 95% CrI: 0.6–1.4%) is considerably lower
than among males (4.0%, 95% CrI: 3.6–4.5%), and the esti-
mated number of HCV Ab+male Malays (281,400, 95%
CrI: 249,400–318,300) is much higher than the numbers
for the other two ethnicity groups (50,200 and 35,000 male
Chinese and male Indian/other, respectively) (Figure 3).
Figure 2 Epidemiological situation for HIV and HCV infection in Malaysia, as of end 2009. Capped lines indicate 95% credible intervals.
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The estimated adult population prevalences according
to ethnicity group are 2.9%, 1.1%, and 0.6%, for Malays,
Chinese, and Indian/other, respectively. The prevalences
according to ethnic group do not closely follow the ethni-
city proportions in the general population, because of dif-
ferences in the prevalence of PWID and the prevalence of
HCV infection in PWID between ethnic groups.
The posterior estimate for the female:male prevalence
ratio among those with non-PWID risk was 0.73 (95% CrI:
0.53–0.98), yielding sex-specific estimates of the infected
population with non-PWID risk of 106,900 and 78,050, for
males and females, respectively. The estimated percentage
of all HCV Ab+ persons whose infection is attributable to
non-PWID transmission is 41% (95% CrI: 32–50%).
Sensitivity to P(PWID)
The results of simulations using alternative values for
the average duration of injecting (which defined the ces-
sation probability) and for excess mortality when model-
ling the PWID population size indicated that the main
outcome – the overall prevalence of HCV – was not overly
sensitive to the original choices for these parameters. The
range of estimates for the median population prevalence
of HCV produced by the sensitivity analyses was 2.15 to
2.83% (see Additional file 1: Appendix C).
Discussion
This study is the first to quantify the epidemiological situ-
ation in Malaysia at the national level in terms of preva-
lence and distribution over modes of transmission. By
combining all of the available – albeit sparse – evidence
within a single statistical framework, we were able to esti-
mate the epidemiological parameters of interest, and un-
certainty around these parameters. Approximately 454,000
persons (2.5% of 15–64 year-olds [33]) were estimated to
be living with HCV infection in 2009. Although the major-
ity of HCV infections occur in PWID, the non-PWID risk
group still represents a large proportion (41%) of the HCV
Ab+ population; this situation differs from that in coun-
tries such as Australia and the UK, where 80% or higher
of prevalent infections are attributable to injecting drug
use [15,34,35].
Stratification by sex and ethnicity was revealing; given
that differences in HCV Ab+ prevalence between Malay
PWID – in whom the highest prevalence was estimated –
and the other ethnic groups may be associated with ethnic
differences in injecting behaviours, and given that only
a small percentage of women are PWID, the estimated
HCV Ab+ prevalence among strata does not simply mirror
the sex and ethnicity distribution in the population.
Our estimated overall prevalence of 2.5% in persons aged
15–64 years is consistent with the findings of the Global
Burden of Disease (GBD) 2010 study, which estimated
HCV Ab+ prevalence at the GBD region level for the
year 2005 using a hierarchical modelling approach [36].
For the Southeast Asia GBD region, overall prevalence
was estimated at 2.0% (95% CI of 1.7-2.3). Within the coun-
tries of the WHO Western Pacific Region (WPR), Malaysia
occupies an upper tier in terms of HCV prevalence; of the
WPR countries with prevalence estimates available, it is
comparable to Vietnam, with a population prevalence
of 2–2.9% [37] but lower than China (3.2% [9]).
Despite the strengths of the modelling approaches used,
this study has a number of limitations. We emphasise that
deriving estimates of epidemiological parameters from mul-
tiple data sources depends heavily on the degree of ac-
curacy, representativeness, and bias in those sources; in
the case of sparse available data (such as the situation in
Malaysia), these factors are even more crucial for produ-
cing valid estimates. Additional data informing any of the
key parameters may result in revised estimates.
The second limitation concerns the extremely simple
model of the prevalent number of active and ex-PWID.
The cessation probability (moving from active to ex-PWID)
Figure 3 Estimated prevalent number of HCV Ab+ infected persons according to ethnicity, sex, and mode of transmission. Capped lines
indicate 95% credible intervals.
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and the relapse probability were not based on evidence,
and the probability of becoming an active PWID was fitted
to a single data point. The dynamic model of the PWID
population also disregards individual heterogeneity in the
drug-using population regarding age at commencement,
age at cessation, and mortality risk. The obtained ratio of
ex- to active PWID (1.34 to 1) is comparable to the ratio
estimated for England (1.95, 95% CrI: 0.72–4.81) using a
different approach and informed by much more data [38];
however, the similarity to the ratio for England cannot be
considered as validation. Despite the assumptions made for
the parameters of the PWID population model, sensitivity
analyses indicated – for cessation probability and excess
mortality at least (see Additional file 1: Appendix C) – that
the principal result was not unduly influenced by the
parameter values chosen.
Our estimate of prevalence within the non-PWID popu-
lation depends on the testing of blood donors carried out
more than 20 years previously [19]. There are two points
of concern regarding the use of this data source to inform
the prevalence in non-PWID. First, despite the study au-
thors taking care to ensure that donors were volunteers
and that individuals with high-risk behaviours were ex-
cluded, obtained seroprevalence values nevertheless could
reflect inclusion of some individuals with a history of inject-
ing drugs. Second, although we adjusted for the specificity
of the second generation assays used at that time, we have
no way to determine if the prevalence in this population
has increased, decreased, or remained stable since. A study
among blood donors conducted in 2008–2009 in north-
eastern Malaysia reported a HCV seroprevalence of 0.45%
[20], but donor pre-screening for blood-borne virus risk
factors has become much more stringent compared with
the early 1990s. However, in the absence of new data, one
could investigate the impact on results when other plaus-
ible values are substituted for this parameter. Further
sensitivity analyses could be useful for examining the im-
pact on parameter estimates from alternative assumptions
about the data.
Finally, the uncertainty associated with the model pa-
rameters – although correctly propagated from all data
sources/parameters concerned – is somewhat under-
estimated due to the lack of a realistic level of uncer-
tainty around the prevalence of active and ex-injectors
(P(PWID)).
Conclusion
The prevalent number of individuals living with HCV infec-
tion in Malaysia is estimated to be very high. To reduce the
considerable – and inevitable – future public health and
economic burden due to morbidity and mortality from se-
vere liver-related disease, current prevention and screening
initiatives and the numbers of chronically infected individ-
uals receiving antiviral treatment will need to be drastically
scaled up. The proposed methodology may be of value for
other countries with a limited evidence base, and for whom
HCV infection is a growing public health issue.
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